Latest Mantle cell lymphoma Stories
SUNNYVALE, Calif., Feb. 12, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S.
Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease.
Blinatumomab, the first BiTE® antibody to be developed for the treatment of cancer, is being investigated by the ECOG-ACRIN Cancer Research Group in its latest trial, E1910. Philadelphia,
RARITAN, N.J., Jan.
WHITE PLAINS, N.Y., Jan.
- A hairdresser.